New and experimental HIV treatments: latest news

New and experimental HIV treatments features

New and experimental HIV treatments in your own words

New and experimental HIV treatments news from aidsmap

More news

New and experimental HIV treatments news selected from other sources

  • Top 10 HIV Clinical Developments of 2016

    In typical years, a noteworthy development in the world of HIV would be the result of a landmark clinical trial or perhaps a gem of a lab study with a novel finding. But, 2016 was not typical. What made the most difference for people living with HIV and their health care providers this past year was less a paper published or presented than major shifts in our thinking about how best to prevent and manage HIV infection.

    02 December 2016 | The Body Pro
  • China to approve 1st long-acting injection to treat HIV/AIDS

    China's national drug authority on Wednesday examined clinical research results on a domestically produced anti-HIV drug in its final phase prior to officially approving the drug. Once approved, the new-generation drug, named Albuvirtide for Injection, is expected to be the world's first long-acting injection for HIV treatment.

    25 November 2016 | Global Times
  • ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen

    Studies will investigate monthly dosing with injectable cabotegravir and rilpivirine

    21 November 2016 | ViiV press release
  • ‘Hard’ Brexit would delay access to new drugs, warns report

    UK patients could see delays in access to new medicines if Brexit means leaving the single market, warns a new report published by think tank Public Policy Projects backed by health consultancy giant QuintilesIMS.

    09 November 2016 | Pharma Times
  • GSK discontinues development of maturation inhibitor BMS-986173

    This is disappointing news as maturation inhibitors would expect to be active about HIV that is multi-drug resistant to HIV medicines from other classes.

    31 October 2016 | HIV i-Base
  • Two Thirds of Oral PrEP-Using MSM Would Switch to Long-Term Shots

    One third of men who have sex with men (MSM) using daily oral PrEP for a year or more would "definitely switch" to a long-acting PrEP shot every 3 months, while another third would "probably switch," according to results of a 90-man survey. Hispanic and nonwhite men were significantly more likely to be among definite switchers.

    26 October 2016 | NATAP
  • More Surprises From ÉCLAIR: Cabotegravir's 'Long Tail'

    The long-acting injectable cabotegravir (ViiV Healthcare), a novel HIV prevention therapy, can persist in the body for more than a year in some people, surprising new data from the phase 2a ÉCLAIR study show. "It's an important finding because you need to give patients some sense of when that protection ends," said Jeanne Marrazzo, MD, from the University of Alabama at Birmingham.

    26 October 2016 | Medscape (requires free registration)
  • New nanomedicine approach aims to improve HIV drug therapies

    New research led by the University of Liverpool aims to improve the administration and availability of drug therapies to HIV patients through the use of nanotechnology.

    24 October 2016 | Science Daily
  • Ask A Pharmacist: With a new tenofovir, should you switch to Descovy, Genvoya or Odefsey?

    I’ve heard more than a few patients ask, what should I do? If I’m already taking Complera, Stribild or Truvada, should I switch to the newer drug formulation with tenofovir alafenamide (TAF)?

    20 September 2016 | BETA blog
  • Janssen Submits Marketing Authorisation Application for Darunavir-Based Single Tablet Regimen for Treatment of HIV-1 to European Medicines Agency

    If approved, this tablet would be the first protease inhibitor-based STR option indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 infection in adults and adolescents. This new treatment would combine the protease inhibitor, darunavir (DRV, D, 800 mg), with the pharmacokinetic enhancer, cobicistat (COBI, C, 150 mg) and the nucleoside reverse transcriptase inhibitors emtricitabine (FTC, F, 200 mg) and tenofovir alafenamide (TAF 10 mg), in one single tablet.

    13 September 2016 | Janssen-Cilag press release
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.